Please ensure Javascript is enabled for purposes of website accessibility
Cabot Prime Plus Logo
Cabot Prime Plus

Cabot Prime Plus Week Ending April 15, 2022

We are making the first issue of Cabot SX Crypto Advisor available to Prime Plus members with our compliments. You can download your free issue here.

Stock Recommendation Tracker

The Stock Recommendation Tracker is a table that features all of the current recommendations in all of our portfolios. It’s a quick way for you to see what stocks are currently in our portfolios and will highlight new additions or any changes to our recommendations over the previous week. We include this table at the bottom of the Weekly Summary, and provide a link here at the top to the Stock Recommendations Tracker.

Cabot Weekly Review (Video)

In this week’s stock market video, Mike Cintolo talks about the market’s latest slide and the damage it’s done to many areas of the market. Because of that, he’s certainly not flooring the accelerator, but he also doesn’t this all of the good vibes from the past month or two (positive divergences, intermediate-term green light, etc.) have been wiped away. He’s still taking it slow, but Mike goes over many names that are hanging in there, including some intriguing commodity stocks that have tightened up.


Cabot Prime Insider Live Analyst Briefing with Q&A: 2nd Quarter 2022

FREE MEMBER BRIEFING: April 13, 2022 Sign up now.

The New Dawn of Dividends and Value

FREE MEMBER BRIEFING: April 21, 2022 Sign up now.

Cabot Retirement Club Live Analyst Briefing with Q&A

FREE MEMBER BRIEFING: April 28, 2022 Sign up now.

Advisory Services

Cabot Growth Investor

Bi-weekly Update April 13: Remain cautious. The Cabot Tides buy signal has fallen by the wayside, and bigger picture, few growth stocks have been able to punch out to new (or multi-month) highs without selling off—thus, we remain cautious, holding plenty of cash and not allowing anything to run away on the downside.

Alert April 12: Remain cautious. The market’s latest selloff has continued this week, with even this morning’s good-looking gap higher disintegrating by day’s end. The brief Cabot Tides buy signal has been erased, and few individual stocks are making any headway. In the Model Portfolio, we think it’s best to cut bait with Dutch Bros. (BROS), which has a story we love, but the failed breakout last month and bearish action since tells us to cut the loss.

Bi-weekly Issue April 7: The market’s evidence improved under the surface for much of February and early March, with the strong rally last month only adding to the good vibes. A pullback wasn’t unexpected, but so far, the way things have retreated hasn’t been encouraging, with a lot of potential leaders taking it on the chin and our nascent Cabot Tides buy signal back on the fence.

Cabot Top Ten Trader

Movers & Shakers April 14: After an ugly couple of weeks, the major indexes got off to a poor start on Monday, but have since stabilized as we cruise into the holiday weekend. Coming into today, the S&P 500 and Nasdaq are down less than 1%, while the broader indexes are actually up 1% or so.

Weekly Issue April 11: This week’s list is heavy on some cyclicals but also some dependable growth outfits. Our Top Pick looks to be one of those, a medical firm with a few good-selling drugs on the market and sold earnings growth projections.

Cabot Undervalued Stocks Advisor

Weekly Update April 13: In a market that is transitioning from 10-year Treasury yields of below 1% (essentially zero) to “not zero” and perhaps 10-year Treasury yields that could reach 3% or higher, valuations increasingly matter.

Monthly Issue April 6: The first quarter was kind to our stocks, as they rose, on average, +8.8%, while the broad market fell. We comment on the sources of the gains and any recent news on our recommended stocks.

Cabot Stock of the Week

Weekly Issue April 11: Today’s recommendation is a well-known pharmaceutical giant whose stock recently broke out above the high it hit in 2000, 22 years ago! But that’s not why it’s recommended today. Today’s story is all about new drugs and renewed growth.

Cabot Explorer

Bi-weekly Issue April 14: Explorer recommendations were pretty flat this week but demonstrated some strength as well. JPMorgan led the banks, reporting a first quarter with a net profit of $8 billion on over $32 billion of revenue. Keep your perspective and play defense and offense. Emerging markets offer you both and we will be adding to the portfolio selectively. This week I highlight a defensive healthcare play of the highest quality.

Bi-weekly Update April 7: The rise in interest rates and the Russia-Ukraine situation are roiling markets and the Fed will soon begin reducing its $9 trillion holdings of Treasury bonds, putting a dent in liquidity that was propping up markets. This is impacting stocks, especially the tech-heavy Nasdaq market.

Cabot Small-Cap Confidential

Update April 14: The world is still a mess with crosscurrents galore. But we will soon have something somewhat concrete to focus our attention on. Yes, I’m talking about first-quarter earnings season.

Monthly Issue April 7: Tyler’s new recommendation Silvergate Capital (SI) is a commercial bank located in La Jolla, CA providing financial infrastructure and services to the digital currency industry. It has a market cap of $3.6 billion.

Cabot Dividend Investor

Monthly Issue April 13: The market situation is changing. Amidst persistent high inflation and concerns about future economic and earnings growth, investors are adjusting. Energy is up nearly 40% YTD as that sector benefits from inflation. Utilities and Consumer Staples are also thriving as investors focus on value, defense, and income in the market uncertainty.

Weekly Update April 6: The big market rebound has petered. And ugliness might be resuming. The waning of war panic and relief about the Fed’s March 0.25% rate hike have given way to new concerns. There may be a new round of economic fallout from the war as Europe proposes additional sanctions on Russia.

Cabot Early Opportunities

Alert March 31: Ratings Updates: Sell CNXC and IBM. We’ve enjoyed a nice snap-back rally in the broad market in recent weeks. This has helped us recover some of the “lost” gains in older positions while pumping paper gains in newer ones.

Monthly Issue March 16: The broad market has been going down since the beginning of the year. The S&P 500, Dow, Nasdaq and S&P 600 Small Cap Index are all below both their 50- and 200-day moving average lines. The same can be said for most sector ETFs in both the large- and small-cap asset classes, save areas like energy and utilities. In short, it is a bear market. And in this environment, before we buy any stock we have to ask ourselves – what’s the downside risk?

Cabot Profit Booster

Alert April 14: Today is the expiration of April options. Because I am on vacation this week I won’t dive deep into the profits, and one potential loss, for these positions until next week. However, most importantly, for today the “headline” is that you don’t need to act on any of our April positions.

Weekly Issue April 12: With commodities and energy stocks still holding up, though, today I’m adding an American company engaged in hydrocarbon exploration: Marathon Oil (MRO).

Cabot Micro-Cap Insider

Monthly Issue April 13: The company that I’m recommending today is a perfect example. It provides the “picks and shovels” to the massive Alzheimer’s market. It is growing revenue at a 20%+ clip yet trades at only 33x earnings (not revenue!). An opportunity like this would not exist in the large-cap market. With that, with that, let’s dive into my latest idea, Cogstate (COGZF).

Weekly Update April 6: This week, everyone is talking about the yield curve inversion. What’s a yield curve inversion? Its when the yields on long-term government bonds are lower than the yields on short-term government bonds.

Cabot Income Advisor

Weekly Update April 13: It’s earnings season. This should be an interesting one. Earnings have saved and rejuvenated the bull market throughout the pandemic recovery. Can this earnings season save the current floundering market?

Monthly Issue March 23: Sure, the rally in the overall market may not last, but this unusual environment is still creating great opportunities in certain pockets if you know where to look. One such opportunity exists in the new and rapidly growing marijuana industry.

Cabot Turnaround Letter

Weekly Update April 14: This week we review earnings from one of our recommended companies and provide updates on three other recommended companies. We share some thoughts on why what produced the remarkable bull market over the past decade and longer may not lead to investing success over the next 5-8 years.

Monthly Issue March 30: All companies are collections of assets. When companies are struggling, a new CEO can redirect how those assets are utilized – a valuable catalyst for a turnaround. We highlight three recent CEO changes and how they might help drive up the value of their companies.

Cabot Money Club

Monthly Magazine April 1: No matter where you are in your investing journey, this comprehensive list has a saving, spending, or investing app that can help you reach your goals.

Stock of the Month March 18: Clif Droke, Chief Analyst for Cabot’s SX Gold & Metals Advisor, advised me that he had traded out of our latest recommendation, the iPath Series B Bloomberg Tin Subindex Total Return ETN (JJT). But he also noted that he would be looking to trade back into the investment in the near future. This is what Clif had to say:

Cabot ETF Strategist

Monthly Issue April 12: In this month’s issue, we focus on the smaller, and lesser known ETFs featured in the undiscovered portfolio. While asset allocation is a tried-and-true method for longer-term investing, you can boost your return with ETF trading. That’s what the undiscovered portfolio is designed to do. With market volatility remaining, this portfolio gives you an opportunity to capture excess returns from asset classes outperforming the broader market.

Weekly Update April 5: Today, I want to address some questions about the Cabot ETF Strategist. I’ve had a few readers ask about trades. The ETF Strategist features two categories of portfolios.

Ask the Experts

Cabot Top Ten Trader

Question: Mike, I have been subscribed with Cabot Wealth for many years. You and your partners have provided a lot of wisdom in this market for this simple-minded dad. I have owned SHOP for several years and thankfully have a base at $177. I have been on the ride UP and have braced on the DOWNSIDE. I added some options at $600 ( May 2022) hoping that $600 is the base. I would greatly appreciate your thought on SHOP over the next several months as I think they have an outstanding company.

Mike:Thanks for writing. Well, two thoughts.My main thought is the stock has likely topped out for a long time – I think its big run is over, or at least, it’s past its point of peak perception. I’m more interested in looking for the next SHOP, so to speak.Second, though, could the stock rally nicely at some point? Yes. I’m not saying it’s going to 300, and maybe it bounces to 1,000 sort of thing in the next rally. But I’d be surprised if it really gets up and goes back to its highs quickly – possible I guess, but unlikely in my view.Thus, I’m not saying you have to dump stuff here, but to me the next bull cycle for growth should be led by other stocks – thus, if it were me, I might look to piece out of some on the way up over time on rallies, and look for new leadership.SHOP was an all-timer, and I’m not saying it’s going to sink 50%, but I think its major run is likely over in terms of leadership.

Quarterly Cabot Analyst Meeting

The recording of the Cabot Prime Members Meeting with the Analysts from January 12, 2022 is now available for you to listen to at your convenience—click here for access. This private call with our analysts is one of your exclusive Cabot Prime Pro member benefits.